心脏手术中行左心耳封堵以预防卒中
该多中心随机试验纳入合并房颤且CHA2DS2-VASc评分≥2、因其他指征接受心脏手术的患者,随机分为同期行或不行左心耳封堵两组,所有患者随访期间均接受常规治疗包括口服抗凝。主要终点为缺血性卒中(含神经影像阳性的短暂性脑缺血发作)或系统性栓塞。平均随访3.8年,封堵组主要终点发生率为4.8%,无封堵组为7.0%(HR 0.67;95%CI 0.53~0.85;P=0.001),围术期出血、心力衰竭或死亡无显著差异。
要点
- 合并房颤且CHA2DS2-VASc评分≥2、因其他指征行心脏手术者,同期左心耳封堵使缺血性卒中或系统性栓塞从7.0%降至4.8%(HR 0.67;95%CI 0.53~0.85;P=0.001)。
- 封堵组与无封堵组围术期出血、心力衰竭或死亡无显著差异。
- 3年时76.8%的患者仍在接受口服抗凝治疗,获益是在继续抗栓治疗基础上观察到的。
- 92.1%的参与者接受了 assigned 手术操作,平均随访3.8年。
适用人群与场景
- 合并房颤且CHA2DS2-VASc评分至少2分(0~9分,评分越高卒中风险越高)、因其他指征计划接受心脏手术的患者。
诊断标准与关键阈值
- 房颤患者卒中风险采用CHA2DS2-VASc评分评估,评分至少2分(0~9分)为纳入标准。
处置流程与药物剂量
- 心脏手术同期行左心耳封堵;所有参与者随访期间均接受常规治疗,包括口服抗凝。
研究设计与关键结果
- 多中心随机试验,主要分析人群封堵组2379例、无封堵组2391例,平均年龄71岁,平均CHA2DS2-VASc评分4.2,平均随访3.8年。
- 92.1%的参与者接受了 assigned 手术操作,3年时76.8%的参与者继续接受口服抗凝治疗。
- 封堵组114例(4.8%)发生卒中或系统性栓塞,无封堵组168例(7.0%)(HR 0.67;95%CI 0.53~0.85;P=0.001)。
- 围术期出血、心力衰竭或死亡的发生率两组无显著差异。
证据类型、等级与局限
- 多中心随机试验(LAAOS III,NCT01561651);参与者、研究人员和初级保健医生(外科医生除外)对分组分配不知情。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于合并房颤且CHA2DS2-VASc评分至少2分、因其他指征接受心脏手术的患者,同期行左心耳封堵可降低缺血性卒中或系统性栓塞风险,且不增加围术期出血、心力衰竭或死亡。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Surgical occlusion of the left atrial appendage has been hypothesized to prevent ischemic stroke in patients with atrial fibrillation, but this has not been proved. The procedure can be performed during cardiac surgery undertaken for other reasons.
METHODS: We conducted a multicenter, randomized trial involving participants with atrial fibrillation and a CHA2DS2-VASc score of at least 2 (on a scale from 0 to 9, with higher scores indicating greater risk of stroke) who were scheduled to undergo cardiac surgery for another indication. The participants were randomly assigned to undergo or not undergo occlusion of the left atrial appendage during surgery; all the participants were expected to receive usual care, including oral anticoagulation, during follow-up. The primary outcome was the occurrence of ischemic stroke (including transient ischemic attack with positive neuroimaging) or systemic embolism. The participants, research personnel, and primary care physicians (other than the surgeons) were unaware of the trial-group assignments.
RESULTS: The primary analysis population included 2379 participants in the occlusion group and 2391 in the no-occlusion group, with a mean age of 71 years and a mean CHA2DS2-VASc score of 4.2. The participants were followed for a mean of 3.8 years. A total of 92.1% of the participants received the assigned procedure, and at 3 years, 76.8% of the participants continued to receive oral anticoagulation. Stroke or systemic embolism occurred in 114 participants (4.8%) in the occlusion group and in 168 (7.0%) in the no-occlusion group (hazard ratio, 0.67; 95% confidence interval, 0.53 to 0.85; P = 0.001). The incidence of perioperative bleeding, heart failure, or death did not differ significantly between the trial groups.
CONCLUSIONS: Among participants with atrial fibrillation who had undergone cardiac surgery, most of whom continued to receive ongoing antithrombotic therapy, the risk of ischemic stroke or systemic embolism was lower with concomitant left atrial appendage occlusion performed during the surgery than without it. (Funded by the Canadian Institutes of Health Research and others; LAAOS III ClinicalTrials.gov number, NCT01561651.).
参考来源
- Whitlock RP, Belley-Cote EP, Paparella D, et al. Left Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke. N Engl J Med. 2021. PMID: 33999547. doi:10.1056/NEJMoa2101897
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。